Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century
Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century
复制标题
DOI：
10.1111/bjh.13537
复制
发表时间：
2015-10-01
影响因子：
6.5
通讯作者：
Brenner, Hermann
中科院分区：
文献类型：
--
作者：
Pulte, Dianne;Jansen, Lina;Brenner, Hermann
多发性骨髓瘤是一种慢性、不可治愈但高度可治疗的肿瘤。最近基于人群的研究表明，在世纪早期诊断的患者的生存率有所改善。在这里，我们研究了2002年至2010年期间德国和美国（US）诊断为多发性骨髓瘤患者的生存趋势。数据来自德国11个基于人群的癌症登记处和美国的监测、流行病学和最终结果数据库。纳入了1997年至2010年期间来自德国和美国的15-74岁诊断和随访的骨髓瘤患者。采用周期分析评估2002-04年至2008-10年期间德国和美国5年相对生存率的趋势。在2002-04年和2008-10年之间，德国和美国的5年相对生存率分别从47.3%和39.8%增加到53.8%和53.2%。年龄梯度较大的患者生存率较低，随着时间的推移持续存在，并且在德国比美国更明显。在世纪的第一个十年中，75岁以下诊断为多发性骨髓瘤的患者的5年相对生存率估计值稳步增加，在德国和美国均达到50%以上的水平，这可能反映了骨髓瘤治疗中新型药物的使用增加。
Multiple myeloma is a chronic, incurable but highly treatable neoplasm. Recent population-based studies have shown improvements in survival for patients diagnosed in the early 21st century. Here, we examine trends in survival for patients diagnosed with multiple myeloma in Germany and the United States (US) between 2002 and 2010. Data were extracted from 11 population-based cancer registries in Germany and from the Surveillance, Epidemiology and End Results database in the US. Myeloma patients aged 15-74 years with diagnosis and follow-up between 1997 and 2010 from Germany and the US were included. Period analysis was employed to assess trends in 5-year relative survival in Germany and the US between 2002-04 and 2008-10. Age-adjusted 5-year relative survival increased from 47.3% to 53.8% in Germany and from 39.8% to 53.2% in the US between 2002-04 and 2008-10. There was a strong age gradient with lower survival among older patients, which persisted over time and was more pronounced in Germany than the US. Five-year relative survival estimates for patients diagnosed with multiple myeloma below 75 years of age steadily increased throughout the first decade of the 21st century and reached levels above 50% in both Germany and the US, probably reflecting the increased use of newer agents in myeloma treatment.